Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Bristol Stuck In Waiting Game As Opdivo TMB Gamble Fails To Pay Off

Jan 25 2019

• By Emily Hayes

high contrast image of casino roulette in motion - Image

Related Content

Bristol's Opdivo/Yervoy Bid Will Show Whether Tumor Mutation Burden Is Ready For Prime Time

Feb 06 2018

Bristol Values Celgene's Hematology, Immunology Portfolio At $74bn, But Does It Price In Risk?

Jan 04 2019

Amid PD-1 Uncertainty, Bristol Under Pressure For M&A Activity

Oct 25 2018

Merck's Keytruda Enjoys Clean Sweep In Lung Cancer, At Bristol's Expense

Apr 17 2018

Roche's Tecentriq Becomes Second In PD-1/L1 Family To Gain First-Line Lung Cancer Approval

Dec 07 2018

CAR-T Forecast: Celgene Follows, But Also Leads As Next Batch Of T-Cell Therapies Near Market

Jan 04 2019

TMB Biomarker Is A Winding Path Rather Than Straight Road

Jun 14 2018

Related Companies

Bristol Myers Squibb Company

Merck & Co., Inc.

Roche Holding AG

Bristol Myers Squibb Company

Additional Topics

ImmunoOncology Sales & Earnings Business Strategies M & A Commercial BioPharmaceutical

More from Immuno-oncology

More from Anticancer

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window